On June 17, 2009, OptoLight Vision Technology announced that it received a CE mark for its Lipshitz Macular Implant (LMI), named for its inventor, Isaac Lipshitz. This will allow OptoLight to immediately begin marketing the implant in Europe and other markets outside of the United States.
On December 28, 2007, Optolight Vision Technology announced success from implantation of the LMI, which is a second generation of the implantable miniature telescope (IMT).
Researchers at Dr. Agarwal’s Eye Hospital and Eye Research Centre, Chennai, India, investigated visual and surgical outcomes of the intraocular mirror telescopic intraocular lens implanted in patients with bilateral macular pathology and visual acuity worse than 20/200 in whom vision improved with a X2.5 external telescope preoperatively. They reported that the LMI may be an effective solution for optical rehabilitation of patients with ARMD or other macular pathology by increasing the central image on the retina while preserving peripheral vision. This preservation of the peripheral field is the main difference between the LMI and the IMT, allowing it to be implanted in both eyes. The abstract of this research was published online at www.sciencedirect.com.